uti and glp-1 Can semaglutide cause UTI? What the research actually shows GLP-1 receptor agonists and next-generation

The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.

Non-Prescription Solutions

*Only available if prescribed after an online consultation with a healthcare provider

Heartburn and acid reflux are common experiences for people starting GLP-1 therapy, but multiple evidence-based approaches can reduce symptoms while you continue your weight loss journey with semaglutide

You want help without visiting a clinic or discussing your drinking face-to-face right now

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication